VANCOUVER – InMed Pharmaceuticals Inc. (NASDAQ: INM), a company specializing in rare cannabinoids and proprietary cannabinoid analogs, has announced promising preclinical data for INM-901, its potential treatment for Alzheimer’s disease (AD).
The recent studies suggest that INM-901 acts as a preferential signaling agonist for cannabinoid receptors CB1 and CB2, and affects the peroxisome proliferator-activated receptor (PPAR) signaling pathway.
Dr. Eric Hsu, Senior Vice President of Preclinical Research and Development at InMed, highlighted the significance of these findings in addressing the multifaceted nature of AD. The data indicates that INM-901 could play a role in reducing neuroinflammation and improving neuronal function, which are critical factors in the progression of AD.
The CB1 and CB2 receptors, part of the endocannabinoid system, are widely distributed in the brain and have been associated with memory, cognition, and motor functions. Their activation has demonstrated neuroprotective effects, which could be beneficial in AD where neuronal death is a major concern.
PPARs, on the other hand, are nuclear hormone receptors that influence various metabolic processes in the body. Their involvement in AD treatments is being explored due to their potential to modulate neuroinflammation and contribute to neuroprotection.
InMed is planning to expedite the development of its AD program, with long-term behavioral and receptor interaction studies expected to produce results by the third quarter of 2024. The company is also progressing with the chemistry, manufacturing, and controls (CMC) for INM-901’s drug substance and oral drug product formulation.
Current AD treatments mainly target symptoms and beta-amyloid plaque reduction but do not address neuron restoration or reverse disease progression. Given the limited treatment options and significant side effects associated with existing AD medications, InMed’s research into INM-901 could offer a new therapeutic approach for this debilitating condition.
The pharmaceutical industry continues to seek effective treatments for AD, with several major companies, including Eli Lilly (NYSE:) and Biogen (NASDAQ:), involved in research and commercialization efforts. InMed’s announcement is based on a press release statement and represents a step forward in the ongoing battle against Alzheimer’s disease.
InvestingPro Insights
InMed Pharmaceuticals Inc. (NASDAQ: INM) has been navigating financial waters that reflect both strengths and challenges, according to recent metrics from InvestingPro. With a market capitalization of just $2.12 million USD, the company is relatively small, which can often lead to higher volatility in stock performance.
This volatility is evident in the price metrics, with the stock having taken a significant hit over the last six months, showing a 48.3% decline. Moreover, the one-year price total return as of 2024 stands at a stark -67.59%, highlighting the rough terrain the company’s stock has traversed recently.
While the financials indicate that InMed has been quickly burning through cash, it’s worth noting as an InvestingPro Tip that the company holds more cash than debt on its balance sheet. This could provide some cushioning against financial stress in the short term.
Still, the company’s revenue growth presents a brighter spot, with a substantial increase of 239.77% in the last twelve months as of Q2 2024. This suggests that despite the current challenges, there is potential for significant growth, which could be bolstered by successful developments in their AD program.
Another InvestingPro Tip to consider is that InMed does not pay a dividend to shareholders, which is typical for companies focusing on reinvesting earnings into research and development. Investors interested in the potential of InMed’s AD treatment may see this as an opportunity for growth rather than immediate income.
For those looking to dive deeper into the financial health and future prospects of InMed Pharmaceuticals, there are additional InvestingPro Tips available, providing a comprehensive analysis of the company’s performance and outlook.
For readers interested in accessing these insights, InvestingPro offers a range of additional tips on InMed Pharmaceuticals. Use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription, which includes a wealth of data to help make informed investment decisions.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
